Indomethacin for intracranial hypertension secondary to severe traumatic brain injury in adults

Autores
Martín Saborido, Carlos; López Alcalde, Jesús; Ciapponi, Agustín; Sánchez Martín, Carlos Enrique; Garcia Garcia, Elena; Escobar Aguilar, Gema; Palermo, Maria Carolina; Baccaro, Fernando G
Año de publicación
2019
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Background: Among people who have suffered a traumatic brain injury, increased intracranial pressure continues to be a major cause of early death; it is estimated that about 11 people per 100 with traumatic brain injury die. Indomethacin (also known as indometacin) is a powerful cerebral vasoconstrictor that can reduce intracranial pressure and, ultimately, restore cerebral perfusion and oxygenation. Thus, indomethacin may improve the recovery of a person with traumatic brain injury. Objectives: To assess the effects of indomethacin for adults with severe traumatic brain injury. Search methods: We ran the searches from inception to 23 August 2019. We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 8) in the Cochrane Library, Ovid MEDLINE, Ovid Embase, CINAHL Plus (EBSCO), four other databases, and clinical trials registries. We also screened reference lists and conference abstracts, and contacted experts in the field. Selection criteria: Our search criteria included randomised controlled trials (RCTs) that compared indomethacin with any control in adults presenting with severe traumatic brain injury associated with elevated intracranial pressure, with no previous decompressive surgery. Data collection and analysis: Two review authors independently decided on the selection of the studies. We followed standard Cochrane methods. Main results: We identified no eligible studies for this review, either completed or ongoing. Authors' conclusions: We found no studies, either completed or ongoing, that assessed the effects of indomethacin in controlling intracranial hypertension secondary to severe traumatic brain injury. Thus, we cannot draw any conclusions about the effects of indomethacin on intracranial pressure, mortality rates, quality of life, disability or adverse effects. This absence of evidence should not be interpreted as evidence of no effect for indomethacin in controlling intracranial hypertension secondary to severe traumatic brain injury. It means that we have not identified eligible research for this review.
Fil: Martín Saborido, Carlos. Universidad Nebrija; España
Fil: López Alcalde, Jesús. No especifíca;
Fil: Ciapponi, Agustín. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentina
Fil: Sánchez Martín, Carlos Enrique. No especifíca;
Fil: Garcia Garcia, Elena. Gobierno de la Provincia de Buenos Aires. Hospital Interzonal Especializado de Agudos y Cronicos San Juan de Dios.; Argentina
Fil: Escobar Aguilar, Gema. Universidad Nebrija; España
Fil: Palermo, Maria Carolina. Universidad de Buenos Aires; Argentina
Fil: Baccaro, Fernando G. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; Argentina
Materia
hypertension
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/148149

id CONICETDig_c7cdcd6482c25f66da3cb8e461d1b114
oai_identifier_str oai:ri.conicet.gov.ar:11336/148149
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Indomethacin for intracranial hypertension secondary to severe traumatic brain injury in adultsMartín Saborido, CarlosLópez Alcalde, JesúsCiapponi, AgustínSánchez Martín, Carlos EnriqueGarcia Garcia, ElenaEscobar Aguilar, GemaPalermo, Maria CarolinaBaccaro, Fernando Ghypertensionhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Background: Among people who have suffered a traumatic brain injury, increased intracranial pressure continues to be a major cause of early death; it is estimated that about 11 people per 100 with traumatic brain injury die. Indomethacin (also known as indometacin) is a powerful cerebral vasoconstrictor that can reduce intracranial pressure and, ultimately, restore cerebral perfusion and oxygenation. Thus, indomethacin may improve the recovery of a person with traumatic brain injury. Objectives: To assess the effects of indomethacin for adults with severe traumatic brain injury. Search methods: We ran the searches from inception to 23 August 2019. We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 8) in the Cochrane Library, Ovid MEDLINE, Ovid Embase, CINAHL Plus (EBSCO), four other databases, and clinical trials registries. We also screened reference lists and conference abstracts, and contacted experts in the field. Selection criteria: Our search criteria included randomised controlled trials (RCTs) that compared indomethacin with any control in adults presenting with severe traumatic brain injury associated with elevated intracranial pressure, with no previous decompressive surgery. Data collection and analysis: Two review authors independently decided on the selection of the studies. We followed standard Cochrane methods. Main results: We identified no eligible studies for this review, either completed or ongoing. Authors' conclusions: We found no studies, either completed or ongoing, that assessed the effects of indomethacin in controlling intracranial hypertension secondary to severe traumatic brain injury. Thus, we cannot draw any conclusions about the effects of indomethacin on intracranial pressure, mortality rates, quality of life, disability or adverse effects. This absence of evidence should not be interpreted as evidence of no effect for indomethacin in controlling intracranial hypertension secondary to severe traumatic brain injury. It means that we have not identified eligible research for this review.Fil: Martín Saborido, Carlos. Universidad Nebrija; EspañaFil: López Alcalde, Jesús. No especifíca;Fil: Ciapponi, Agustín. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; ArgentinaFil: Sánchez Martín, Carlos Enrique. No especifíca;Fil: Garcia Garcia, Elena. Gobierno de la Provincia de Buenos Aires. Hospital Interzonal Especializado de Agudos y Cronicos San Juan de Dios.; ArgentinaFil: Escobar Aguilar, Gema. Universidad Nebrija; EspañaFil: Palermo, Maria Carolina. Universidad de Buenos Aires; ArgentinaFil: Baccaro, Fernando G. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; ArgentinaJohn Wiley & Sons Ltd2019-11info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/148149Martín Saborido, Carlos; López Alcalde, Jesús; Ciapponi, Agustín; Sánchez Martín, Carlos Enrique; Garcia Garcia, Elena; et al.; Indomethacin for intracranial hypertension secondary to severe traumatic brain injury in adults; John Wiley & Sons Ltd; Cochrane Database of Systematic Reviews; 2019; 11; 11-2019; 1-251469-493XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/http://doi.wiley.com/10.1002/14651858.CD011725.pub2info:eu-repo/semantics/altIdentifier/doi/10.1002/14651858.CD011725.pub2info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:02:18Zoai:ri.conicet.gov.ar:11336/148149instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:02:18.885CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Indomethacin for intracranial hypertension secondary to severe traumatic brain injury in adults
title Indomethacin for intracranial hypertension secondary to severe traumatic brain injury in adults
spellingShingle Indomethacin for intracranial hypertension secondary to severe traumatic brain injury in adults
Martín Saborido, Carlos
hypertension
title_short Indomethacin for intracranial hypertension secondary to severe traumatic brain injury in adults
title_full Indomethacin for intracranial hypertension secondary to severe traumatic brain injury in adults
title_fullStr Indomethacin for intracranial hypertension secondary to severe traumatic brain injury in adults
title_full_unstemmed Indomethacin for intracranial hypertension secondary to severe traumatic brain injury in adults
title_sort Indomethacin for intracranial hypertension secondary to severe traumatic brain injury in adults
dc.creator.none.fl_str_mv Martín Saborido, Carlos
López Alcalde, Jesús
Ciapponi, Agustín
Sánchez Martín, Carlos Enrique
Garcia Garcia, Elena
Escobar Aguilar, Gema
Palermo, Maria Carolina
Baccaro, Fernando G
author Martín Saborido, Carlos
author_facet Martín Saborido, Carlos
López Alcalde, Jesús
Ciapponi, Agustín
Sánchez Martín, Carlos Enrique
Garcia Garcia, Elena
Escobar Aguilar, Gema
Palermo, Maria Carolina
Baccaro, Fernando G
author_role author
author2 López Alcalde, Jesús
Ciapponi, Agustín
Sánchez Martín, Carlos Enrique
Garcia Garcia, Elena
Escobar Aguilar, Gema
Palermo, Maria Carolina
Baccaro, Fernando G
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv hypertension
topic hypertension
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Background: Among people who have suffered a traumatic brain injury, increased intracranial pressure continues to be a major cause of early death; it is estimated that about 11 people per 100 with traumatic brain injury die. Indomethacin (also known as indometacin) is a powerful cerebral vasoconstrictor that can reduce intracranial pressure and, ultimately, restore cerebral perfusion and oxygenation. Thus, indomethacin may improve the recovery of a person with traumatic brain injury. Objectives: To assess the effects of indomethacin for adults with severe traumatic brain injury. Search methods: We ran the searches from inception to 23 August 2019. We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 8) in the Cochrane Library, Ovid MEDLINE, Ovid Embase, CINAHL Plus (EBSCO), four other databases, and clinical trials registries. We also screened reference lists and conference abstracts, and contacted experts in the field. Selection criteria: Our search criteria included randomised controlled trials (RCTs) that compared indomethacin with any control in adults presenting with severe traumatic brain injury associated with elevated intracranial pressure, with no previous decompressive surgery. Data collection and analysis: Two review authors independently decided on the selection of the studies. We followed standard Cochrane methods. Main results: We identified no eligible studies for this review, either completed or ongoing. Authors' conclusions: We found no studies, either completed or ongoing, that assessed the effects of indomethacin in controlling intracranial hypertension secondary to severe traumatic brain injury. Thus, we cannot draw any conclusions about the effects of indomethacin on intracranial pressure, mortality rates, quality of life, disability or adverse effects. This absence of evidence should not be interpreted as evidence of no effect for indomethacin in controlling intracranial hypertension secondary to severe traumatic brain injury. It means that we have not identified eligible research for this review.
Fil: Martín Saborido, Carlos. Universidad Nebrija; España
Fil: López Alcalde, Jesús. No especifíca;
Fil: Ciapponi, Agustín. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentina
Fil: Sánchez Martín, Carlos Enrique. No especifíca;
Fil: Garcia Garcia, Elena. Gobierno de la Provincia de Buenos Aires. Hospital Interzonal Especializado de Agudos y Cronicos San Juan de Dios.; Argentina
Fil: Escobar Aguilar, Gema. Universidad Nebrija; España
Fil: Palermo, Maria Carolina. Universidad de Buenos Aires; Argentina
Fil: Baccaro, Fernando G. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; Argentina
description Background: Among people who have suffered a traumatic brain injury, increased intracranial pressure continues to be a major cause of early death; it is estimated that about 11 people per 100 with traumatic brain injury die. Indomethacin (also known as indometacin) is a powerful cerebral vasoconstrictor that can reduce intracranial pressure and, ultimately, restore cerebral perfusion and oxygenation. Thus, indomethacin may improve the recovery of a person with traumatic brain injury. Objectives: To assess the effects of indomethacin for adults with severe traumatic brain injury. Search methods: We ran the searches from inception to 23 August 2019. We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 8) in the Cochrane Library, Ovid MEDLINE, Ovid Embase, CINAHL Plus (EBSCO), four other databases, and clinical trials registries. We also screened reference lists and conference abstracts, and contacted experts in the field. Selection criteria: Our search criteria included randomised controlled trials (RCTs) that compared indomethacin with any control in adults presenting with severe traumatic brain injury associated with elevated intracranial pressure, with no previous decompressive surgery. Data collection and analysis: Two review authors independently decided on the selection of the studies. We followed standard Cochrane methods. Main results: We identified no eligible studies for this review, either completed or ongoing. Authors' conclusions: We found no studies, either completed or ongoing, that assessed the effects of indomethacin in controlling intracranial hypertension secondary to severe traumatic brain injury. Thus, we cannot draw any conclusions about the effects of indomethacin on intracranial pressure, mortality rates, quality of life, disability or adverse effects. This absence of evidence should not be interpreted as evidence of no effect for indomethacin in controlling intracranial hypertension secondary to severe traumatic brain injury. It means that we have not identified eligible research for this review.
publishDate 2019
dc.date.none.fl_str_mv 2019-11
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/148149
Martín Saborido, Carlos; López Alcalde, Jesús; Ciapponi, Agustín; Sánchez Martín, Carlos Enrique; Garcia Garcia, Elena; et al.; Indomethacin for intracranial hypertension secondary to severe traumatic brain injury in adults; John Wiley & Sons Ltd; Cochrane Database of Systematic Reviews; 2019; 11; 11-2019; 1-25
1469-493X
CONICET Digital
CONICET
url http://hdl.handle.net/11336/148149
identifier_str_mv Martín Saborido, Carlos; López Alcalde, Jesús; Ciapponi, Agustín; Sánchez Martín, Carlos Enrique; Garcia Garcia, Elena; et al.; Indomethacin for intracranial hypertension secondary to severe traumatic brain injury in adults; John Wiley & Sons Ltd; Cochrane Database of Systematic Reviews; 2019; 11; 11-2019; 1-25
1469-493X
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://doi.wiley.com/10.1002/14651858.CD011725.pub2
info:eu-repo/semantics/altIdentifier/doi/10.1002/14651858.CD011725.pub2
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv John Wiley & Sons Ltd
publisher.none.fl_str_mv John Wiley & Sons Ltd
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613826224324608
score 13.070432